Seladelpar Reduces Serum IL-31, Improves Pruritus in Patients with Primary Biliary Cholangitis

The post-hoc analysis of the phase 3 ENHANCE study provides the first published evidence of a correlation between decreases in IL-31, bile acids, and pruritus symptoms in PBC following treatment with an investigational agent.

Related Keywords

Zurich ,Züsz ,Switzerland ,Researchgate Andreas Kremer ,Cymabay Seladelpar ,Drug Administration ,University Hospital Zurich ,Andreas Kremer ,Bay Therapeutics ,Breakthrough Therapy Designation ,New Drug Application ,Priority Review ,Pruritis Improvement ,Primary Biliary Cholangitis ,Hoc Analysis ,Primary Biliary ,Cpbc ,Pruritus ,Interleukin 31 ,Il 31 ,Bile Acid ,Seladelpar ,